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SUMMARY 
The effect of high fat food in the steady state bioavailability of lithium carbonate (900 or 1200mg daily, in divided 
doses) was studied in three patients of manic-depressive psychosis in a self-control cross-over design. Serial blood 
samples were collected by venepuncture until 8 hours following drug administration and lithium was assayed by 
flame photometry. The results indicated a reduction in the extent of bioavailability of lithium by the high fat food 
as compared to standard normal diet, in all the three patients studied Caution should be exercised in regard to 
lithium administration along with food rich in fat content. 
INTRODUCTION . 
Lithium carbonate has been the mai nstay of therapy in 
manic-depressive psychosis (MDP) and the very low 
therapeutic index of the drug necessitates careful monitor-
ing of the serum concentrations (Baldessarini, 1991). 
Some of our patients who were duly controlled and stabi-
lized with lithium subsequently presented with recurrence 
of symptoms with less than adequate serum lithium levels, 
although no obvious reason for this was discernible. While 
poor compliance was the first possibility that came to our 
mind, we explored other possible reasons too. 
The influence of food on the bioavailability of drugs is 
well recognized (Toothaker & Welling, 1980). Various 
constituents of food alter the pharmacokinetic profiles of 
drugs in different ways. A higher fat content in food has 
been shown to increase the bioavailability of griseofulvin 
(Crounse, 1961) and to reduce that of tetracycline (Well-
ing, 1977). Lithium carbonate is completely and readily 
absorbed from the gastrointestinal tract. The clinical effec-
tiveness of lithium is said to be increased when it is 
administered with food (Toothaker & Welling, 1980), in 
terms of reduced gastrointestinal irritation and local side 
effects. Besides, most patients tend to take drugs just prior 
to, along with or right after food in order to ensure com-
pliance. The food habit of people in the northern part of 
India is different from that elsewhere in the country, to the 
extent that the fat content is relatively high. It seemed thus 
possible, that in our patients, high-fat meals could alter the 
absorption kinetics of the drug. In the present preliminary 
study, therefore, the possible influence of a high-fat break-
fast on the steady-state bioavailability of lithium carbonate 
was assessed in three patients with Manic depressive 
psychosis (MDP) who were adequately controlled and 
stabilized with 900 to 1200 mg of lithium per day. 
CASE PROFILES 
Patient No.1: PKG, 20 yr old male, 56 kg, 176 cm, 
non-smoker, non-alcoholic, MDP circular currently 
manic, presented with a four month history of irritability, 
hyperactivity, euphoria, grandiosity and transient cogni-
tive deficits. A past history of depression in 1987 (3 
months) and mania in 1989 (6 months) for which no 
detailed history of treatment was available; no family 
history. Laboratory investigations (renal function tests, 
Liver function tests, haemogram and electrocardiogram) 
were within normal limits; He was treated with lithium 
carbonate (Licab R ) Tab 1200 mg daily in divided doses 
under direct supervision, i.e., 300 mg each at 7.00 a.m., 
3.00 p.m. and 600 mg at 11.00 p.m. Other treatment for 
control of manic symptoms (haloperidol, carbamazepine, 
lorazepam) was stopped a week prior to the bioavailability 
study. 
Patient No.2: DA, 19 yr old male, 55 Kg, 173 cm, 
non-smoker, non-alcoholic, MDP circular currently 
manic, presented with a four month history of hyperac-
tivity, restlessness, pressure of speech, elated mood and 
grandiose ideation. A past history of 2 manic and 1 depres-
sive episode in two years, with an average duration of 2 
months each; details of treatment not available. History of 
MDP (mania) in father, no other concomitant disease 
present. Laboratory investigations were (RFT, LFT, 
haemogram and EKG) within normal limits; He was 
treatedwithlithiumcarbonate(Licab )Tab 1200mgdaily 
in divided doses under direct supervision, i.e., 300 mg each 
at 7.00 a.m., 3.00 p.m. and 600 mg at 11.00 p.m. for \
i
a 
months. Other treatment for control of manic symptoms 
(carbamazepine and lorazepam) and for neuroleptic mal ig-
nant syndrome (bromocriptine) were stopped a week prior 
to the bioavailability study. 
Patient NoJ: PS, 47 yr old male, 67 Kg, 178 cm, 
non-smoker, non-alcoholic, MDP circular currently 
manic, presented with a three month history of irritability, 
talkativeness, psychomotor agitation and impaired in-
sight; There was a past history of 3 episodes in last 3 years 
(2 manic and 1 depressive) which were treated with 
neuroleptics and antidepressants. No other concomitant 
disease present; All laboratory investigations (RFT, LFT, 
haemogram and EKG) were within normal limits. He was 
treated with lithium carbonate 900 mg daily in three 
divided doses under direct supervision, i.e., 300 mg each 
at 7.00 a.m., 3.00 p.m. and 11.00 pm for 1 month. Other 
treatment for control of manicsymptoms(chlorpromazine 
and nitrazepam) were withdrawn a week prior to the 
bioavailability study. 
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METHOD 
Following an overnight fast, a standard breakfast (SB: 
comprisi ng of 4 slices of bread, 15 grams of jam and 200ml 
of orange juice) and after a gap of 2 days a high fat 
breakfast (HFB: comprising of 4 slices of bread, 15gmsof 
jam, 200ml of orange juice 200ml and 50 gms of butter, 
Verka ) were givento each patient at 6.50 am and the 
morning dose of lithium was given under direct super-
vision at 7.00 a.m. as usual, along with 200 ml of water. 
All the patients thus served as their own controls. 
Blood samples were collected by venepuncture in 
heparinized tubes on both occasions at 0, 1.5, 3, 5 and 8 
hours following lithium administration. The samples were 
processed and serum lithium was assayed by flame 
photometry. 
The area under the plasma concentration curve (AUC 
0-8) was calculated usi ng trapezoidal rule. The peak serum 
concentration (C max), time to reach the same (t max), and 
the minimum serum concentration (C min) were taken 
from the actual observed values. 
RESULTS 
The Table shows the values of various kinetic 
parameters. 
Lithium kinetic variables in the study subjects 
PatientB  AUC 
0-8 
(meqfl*hr) 
Cmas 
(meg/L) 
Cmin 
(meq/L) 
Tmax 
(hr) 
SB HFB SB HFB SB HFB SB HFB 
PKQ 
DA 
PS 
8.28 
4.58 
8.93 
6.93 
3.69 
7.81 
1.25 
0.70 
1.25 
1.00 
0.60 
0.95 
0.90 
0.40 
0.75 
0.70 
0.35 
0.70 
1.50 
3.00 
3.00 
3.00 
3.00 
3.00 
S0 = standard breakfast; HFB = high-fat breakfast 
In all three patients, the AUC 0-8 was lowered when 
lithium was administered with the high-fat breakfast 
(HFB) as compared to the standard breakfast (SB). The 
HFB also lowered the Cmax and Cmin in all three patients 
as compared to the SB control values. However, in two 
patients, the Tmax values were same with either SB or 
HFB but in the third (PKG), the Tmax increased to 3.0 
hours from its SB control value of 1.5 hours. 
DISCUSSION 
The results suggest that high fat content in the diet can 
reduce the extent of bioavailability of lithium carbonate. 
To the best of our knowledge, an interaction of this kind 
has not been reported earlier. While understanding the 
underlying mechanism for such an interaction is beyond 
the scope of the present preliminary study, it is tempting 
to speculate that the high-fat diet possibly lowered the 
absorption kinetics of lithium. Nevertheless, since lithium 
carbonate is a drug of very low therapeutic index, such 
interaction could pose serious and sudden therapeutic 
problem to a patient with Manic Depressive Psychosis 
who has been otherwise controlled and stabilized with 
lithium carbonate. Though, carried out only in three 
patients, on the basis of this preliminary report the authors 
suggest that when lithium levels are below the therapeutic 
range, the physician, in addition to probing into possible 
compliance failure, should also enquire from his patient 
about any change in the dietary practice in the recent past. 
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